-
公开(公告)号:US10966980B2
公开(公告)日:2021-04-06
申请号:US14822265
申请日:2015-08-10
Applicant: Pfizer Inc.
Inventor: Michael L. Vazquez , Neelu Kaila , Jamison B. Tuttle , Patrick Robert Verhoest , Matthew R. Reese , Karen J. Coffman , Tarek Samad , James M. Duerr , Simone Sciabola , Mihir D. Parikh
IPC: C07D487/04 , C07D519/00 , C07D491/052 , C07D498/08 , C07D491/044 , A61K45/06 , A61K31/519 , A61K31/5377 , A61K31/5386
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
-
公开(公告)号:US10669279B2
公开(公告)日:2020-06-02
申请号:US16455020
申请日:2019-06-27
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young , Patrick Robert Verhoest
IPC: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US10328082B2
公开(公告)日:2019-06-25
申请号:US15314574
申请日:2015-05-18
Applicant: Pfizer Inc.
Inventor: Eugene Lvovich Piatnitski Chekler , Adam Matthew Gilbert , Rayomand Jal Unwalla , Patrick Robert Verhoest , James Thomas Anderson
IPC: A61K31/549 , A61K45/06 , A61K31/277 , A61K31/397 , A61K31/402 , A61K31/433 , A61K31/451 , A61K31/472 , A61K31/4725
Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH2)q—, —(CHRs)q—, or —(CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.
-
公开(公告)号:US10323042B2
公开(公告)日:2019-06-18
申请号:US16074290
申请日:2017-02-15
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Patrick Robert Verhoest , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Travis T. Wager , Matthew Merrill Hayward
IPC: H01L51/00 , C07D498/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US20190055262A1
公开(公告)日:2019-02-21
申请号:US16074290
申请日:2017-02-15
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Patrick Robert Verhoest , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Travis T. Wager , Matthew Merrill Hayward
IPC: C07D498/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
56.
公开(公告)号:US10039753B2
公开(公告)日:2018-08-07
申请号:US15262112
申请日:2016-09-12
Applicant: Pfizer Inc.
Inventor: Karen Jean Coffman , Paul Galatsis , Michelle Renee Garnsey , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Martin Youngjin Pettersson , Matthew Richard Reese , Antonia Friederike Stepan , Patrick Robert Verhoest , Travis T. Wager
IPC: A61K31/435 , C07D215/38 , C07D471/04 , C07D519/00 , C07D471/14 , C07D215/42 , A61K31/4745
CPC classification number: A61K31/435 , A61K31/4745 , C07D215/38 , C07D215/42 , C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
公开(公告)号:US09695171B2
公开(公告)日:2017-07-04
申请号:US15104659
申请日:2014-12-03
Applicant: Pfizer Inc.
Inventor: Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest , Antonia Friederike Stepan
IPC: C07D471/04 , C07D487/04 , C07D519/00 , C07D491/08 , C07D498/08
CPC classification number: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00
Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
公开(公告)号:US20170166566A1
公开(公告)日:2017-06-15
申请号:US15441882
申请日:2017-02-24
Applicant: Pfizer Inc.
Inventor: Martin Youngjin Pettersson , Christopher William am Ende , John Michael Humphrey , Douglas Scott Johnson , Gregory Wayne Kauffman , Danica Antonia Rankic , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b,R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
59.
公开(公告)号:US09611264B1
公开(公告)日:2017-04-04
申请号:US15272820
申请日:2016-09-22
Applicant: Pfizer Inc.
Inventor: Michael Aaron Brodney , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Patrick Robert Verhoest , Romelia del Carmen Salomon Ferrer
IPC: C07D417/14
CPC classification number: C07D417/14
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号:US09598421B2
公开(公告)日:2017-03-21
申请号:US14817606
申请日:2015-08-04
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Patrick Robert Verhoest , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
-
-
-
-
-
-
-
-